 | Review waiting, please be patient.
This may take 6 weeks or more, since drafts are reviewed in no specific order. There are 1,215 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
| Submission declined on 12 October 2024 by SafariScribe (talk). This submission's references do not show that the subject qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published, reliable, secondary sources that are independent of the subject (see the guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see technical help and learn about mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
This draft has been resubmitted and is currently awaiting re-review. |  |
| Submission declined on 10 August 2024 by CFA (talk). This submission does not appear to be written in the formal tone expected of an encyclopedia article. Entries should be written from a neutral point of view, and should refer to a range of independent, reliable, published sources. Please rewrite your submission in a more encyclopedic format. Please make sure to avoid peacock terms that promote the subject. Declined by CFA 2 months ago. | |
Comment: This article has been completely rewritten per editorial feedback and past comments from the previous deletion. Thank you @SafariScribe and @CFA for the excellent feedback and very thoughtful responses to improve the article. 1. The references have been improved including notable 3rd party new sources since the initial submission per @SafariScribe. 2. The draft has been significantly re-written to reflect the past editorial comments @CFA💬 17:47, 11 October 2024 (UTC)
Anand Reddi | |
|---|---|
| Born | Maryland, USA |
| Nationality | American |
| Education | University of Michigan, Ann Arbor, University of Colorado School of Medicine |
| Occupation(s) | Global Health Policy Specialist, Public Health Advocate, Biotech Executive |
| Known for | Advocacy in global HIV/AIDS treatment and health systems strengthening |
| Awards | Fulbright Scholar, American Medical Association Foundation Leadership Award |
Anand Reddi is a health system strengthening expert, global health specialist and public health advocate. His early work focused on global HIV scale-up including the President's Emergency Plan for AIDS Relief (PEPFAR).[1][2][3][4][5][6][7] Since 2015, Reddi works in the biotech industry advancing access to essential medicines and building global public-private health partnerships.[8][9][10][11] He served on several global health not-for-profit board of directors including the AIDS Healthcare Foundation and the Bay Area Global Health Alliance.[12]
- ^ Cite error: The named reference
:2was invoked but never defined (see the help page). - ^ Cite error: The named reference
:3was invoked but never defined (see the help page). - ^ Liu, Richard (19 November 2020). "Atlantic Dialogues Talks 2020: Health Capacities as a New Power Instrument". The Atlantic Dialogues: Policy Center for the New South.
- ^ Purvis, Katherine. "How do we increase the HIV response with limited funds?". The Guardian. Retrieved 6 July 2024.
- ^ Banning-Lover, Rachel. "What is the best model to bring healthcare to all?". The Guardian. Retrieved 19 June 2024.
- ^ Mungcal, Ivy (18 October 2011). "Anand Reddi: PEPFAR at Risk Should Mitt Romney Become US President". Devex.
- ^ Judem, Emily. "An invisible issue: The presidential campaign and HIV/AIDS". The World Radio Program.
- ^ "Pharma companies are capitalizing on Covid-19 restrictions to promote unbranded campaigns". Pharmaceutical Technology Review. Retrieved 23 July 2024.
- ^ Bulik, Beth Snyder (28 Oct 2020). "BI, Gilead execs highlight value of disease awareness campaigns—particularly during the pandemic". Fierce Pharma.
- ^ "Adverum Announces Senior Appointments for Patient Access and Clinical Operations as ADVM-022 Advances Toward Global Phase 3 Trials". The Globe and Mail. 30 March 2021.
- ^ "Hepion Pharmaceuticals Further Strengthens Board with Appointments of Accomplished Biopharmaceutical Executives, Mr. Anand Reddi and Dr. Kaouthar Lbiati". NASDAQ. 28 June 2022.
- ^ "Speaking out on Social/Political issues: CHRO's role in working with CEO". HR Strategy Forum. Retrieved 8 July 2024.